Skip to main content
European Medicines Agency's logo Go to homepage
English
Select your language
българскиespañolčeštinadanskDeutscheestiελληνικάEnglishfrançaisGaeilgehrvatskiitalianolatviešu
lietuviųmagyarMaltiNederlandspolskiportuguêsromânăslovenčinaslovenščinasuomisvenskaÍslenskanorsk
Select how you want to search using keywords
  • Medicines
    • Find medicine
    • Therapeutic areas: latest updates
    • Download medicine data
    • What we publish on medicines and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Medical devices
    • Herbal products
  • Veterinary regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    • Overview
    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    • Overview
    • News
    • Events
    • What's new
    • Committee highlights
    • Publications
    • Press and social media
    • Podcast: Inside EMA
    • Campaigns
    • Speeches
    • Open consultations
    • RSS feeds
  • Partners & networks
    • Overview
    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Academia
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
    • One Health approach
    • Animal health professionals
    • One substance - one assessment
  • About us
    • Overview
    • What we do
    • Who we are
    • How we work
    • Fees
    • Support to SMEs
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • About this website
    • Data protection and privacy
    • Contacts
  1. Home
  2. Medicines
  3. Tivicay - opinion on variation to marketing authorisation

Tivicay - opinion on variation to marketing authorisation

Opinion

EMA has issued an opinion on a change to this medicine's authorisation

dolutegravir
Post-authorisationHuman

Page contents

  • Opinion
  • Key facts
  • News on Tivicay
  • More information on Tivicay

Opinion

On 12 November 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Tivicay. The marketing authorisation holder for this medicinal product is ViiV Healthcare B.V.

The CHMP adopted an extension to an existing indication for Tivicay dispersable tablets, as follows:

Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents, and children and term neonates from birth of at least 4 weeks of age or older and weighing at least 2 3 kg. 

For information, the indication for Tivicay film-coated tablets remain unchanged, as follows:

Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.


New text in bold, removed text as strikethrough

CHMP post-authorisation summary of positive opinion for Tivicay (VR-0000351003)

Adopted Reference Number: EMADOC-1700519818-3536528

English (EN) (117.86 KB - PDF)

First published: 13/11/2026
View

Key facts

Name of medicine
Tivicay
EMA product number
EMEA/H/C/002753
Active substance
dolutegravir
International non-proprietary name (INN) or common name
dolutegravir
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutical chemical (ATC) code
J05AX12
Marketing authorisation holder
ViiV Healthcare BV
Date of opinion
12/11/2026
Status
Positive

News on Tivicay

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026
13/11/2026
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2020
13/11/2020
New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir
18/05/2018
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2016
16/12/2016
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 November 2013
22/11/2013
European Medicines Agency recommends approval of new HIV medicine
22/11/2013

More information on Tivicay

  • Tivicay
This page was last updated on 13/11/2026

Share this page

Back to top

Product emergency hotline

OUTSIDE WORKING HOURS

About us
What we do
Careers
Committees & working parties
Regulatory network
European experts
About this website
Languages
Accessibility
Glossaries
Cookies
Website data protection notice
Data protection at EMA
Frequently asked questions
Search tips
Access to documents
Contacts
Send a question
EMA Service Desk (system support)
Services and databases

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us
Postal address and deliveries
Business hours and holidays

  • RSS Feed
  • BlueskyFollow EMA on Bluesky. Opens in a new window.
  • YouTubeFollow EMA on YouTube. Opens in a new window.
  • LinkedInFollow EMA on LinkedIn. Opens in a new window.
© 1995 - 2026 European Medicines Agency
European Union agencies network
An agency of the European Union